Jennison Associates
PCRX icon

Jennison Associates’s Pacira BioSciences PCRX Stock Holding History

Jennison Associates’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-621,679
Closed -$19.1M – 615
2023
Q3 		$19.1M Sell
621,679
-343,751
-36% -$12.4M 0.02% 320
2023
Q2 		$38.7M Buy
965,430
+139,593
+17% +$5.77M 0.03% 224
2023
Q1 		$33.7M Sell
825,837
-9,468
-1% -$377K 0.03% 249
2022
Q4 		$32.3M Buy
835,305
+38,254
+5% +$1.86M 0.03% 260
2022
Q3 		$42.4M Buy
797,051
+382,680
+92% +$21.3M 0.04% 195
2022
Q2 		$24.2M Buy
+414,371
New +$27.1M 0.02% 289
2018
Q2 		– Sell
-515,132
Closed -$16M – 697
2018
Q1 		$16M Buy
+515,132
New +$18.3M 0.02% 418
2016
Q2 		– Sell
-954,110
Closed -$50.5M – 653
2016
Q1 		$50.5M Buy
954,110
+12,123
+1% +$709K 0.05% 275
2015
Q4 		$72.3M Sell
941,987
-11,889
-1% -$673K 0.07% 226
2015
Q3 		$39.2M Sell
953,876
-718,732
-43% -$44M 0.04% 345
2015
Q2 		$118M Sell
1,672,608
-1,174,059
-41% -$92.5M 0.11% 176
2015
Q1 		$253M Sell
2,846,667
-11,581
-0.4% -$1.18M 0.23% 86
2014
Q4 		$253M Buy
2,858,248
+598,516
+26% +$56.6M 0.24% 87
2014
Q3 		$219M Sell
2,259,732
-270,178
-11% -$26.3M 0.2% 92
2014
Q2 		$232M Sell
2,529,910
-102,906
-4% -$7.84M 0.21% 103
2014
Q1 		$184M Sell
2,632,816
-142,172
-5% -$9.67M 0.18% 117
2013
Q4 		$160M Buy
2,774,988
+156,574
+6% +$8.23M 0.16% 131
2013
Q3 		$126M Buy
2,618,414
+17,040
+0.7% +$621K 0.13% 154
2013
Q2 		$75.4M Buy
+2,601,374
New +$75.3M 0.08% 221

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Frontier Capital Management
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Stephens Investment Management Group
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
Vestal Point Capital
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Jennison Associates's PCRX Position: Q4 2023 in Review

Jennison Associates sold out of Pacira BioSciences (PCRX) in Q4 2023, closing a stake of 621,679 shares — an estimated $19.1M sold.

Jennison Associates first reported a position in PCRX in Q2 2013 and held it in 19 quarters. The position peaked at $253M in Q4 2014. 261 funds tracked by Wall St. Rank hold PCRX as of Q4 2023.

  • Jennison Associates reported no remaining Pacira BioSciences position as of Q4 2023 after selling out during the quarter.
  • Jennison Associates sold 621,679 Pacira BioSciences shares in Q4 2023, an estimated $19.1M.
  • Jennison Associates first reported a position in Pacira BioSciences in Q2 2013 and held it in 19 quarters.
  • Jennison Associates's Pacira BioSciences position peaked at $253M in Q4 2014.
  • 261 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2023.

Based on Jennison Associates's 13F filing for Q4 2023, filed 1 Feb 2024.